These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3284 related articles for article (PubMed ID: 7572760)

  • 1. A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma.
    Antoine EC; Rixe O; Vuillemin E; Benhammouda A; Borel C; Ghironzi GC; Mularoni E; Franks C; Auclerc G; Soubrane C
    Am J Clin Oncol; 1995 Oct; 18(5):421-4. PubMed ID: 7572760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The feasibility of repetitive courses of high-dose continuous intravenous infusion interleukin-2 and subcutaneous alpha-interferon with polychemotherapy in advanced malignant melanoma.
    Foppoli M; Citterio G; Polastri D; Guerrieri R
    Tumori; 1995; 81(2):102-6. PubMed ID: 7778212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma--a pilot study.
    Bernengo MG; Doveil GC; Bertero M; Quaglino P; Fierro MT; Savoia P; Appino A; Colonna S
    Melanoma Res; 1996 Jun; 6(3):257-65. PubMed ID: 8819129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects.
    Keilholz U; Scheibenbogen C; Möhler T; Brossart P; Maclachlan D; Geueke AM; Jochim A; Hunstein W
    Melanoma Res; 1995 Aug; 5(4):283-7. PubMed ID: 7496166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
    Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
    Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin, interleukin-2, interferon-alpha and tamoxifen in metastatic melanoma. A phase II study.
    Naglieri E; Procacci A; Galetta D; Abbate I; Dell 'Erba L; Colucci G
    J Chemother; 1999 Apr; 11(2):150-5. PubMed ID: 10326747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
    Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Seipp CA; Einhorn JH; White DE; Steinberg SM
    J Clin Oncol; 1999 Mar; 17(3):968-75. PubMed ID: 10071291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
    Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
    Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen.
    Feliu J; González Barón M; Chacón JI; Espinosa E; Garrido P; Castro J; Escobar Y; Colmenarejo A; Jara C; García Girón C; Espinosa J; Ordóñez A
    Cancer Chemother Pharmacol; 1996; 38(2):191-4. PubMed ID: 8616911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
    Thompson JA; Gold PJ; Fefer A
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U; Goey SH; Punt CJ; Proebstle TM; Salzmann R; Scheibenbogen C; Schadendorf D; Liénard D; Enk A; Dummer R; Hantich B; Geueke AM; Eggermont AM
    J Clin Oncol; 1997 Jul; 15(7):2579-88. PubMed ID: 9215828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of malignant melanoma: recent advances and perspectives].
    Saida T
    Gan To Kagaku Ryoho; 1997 Jan; 24(1):10-5. PubMed ID: 9020939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
    Stark JJ; Dillman RO; Schulof R; Wiemann MC; Barth NM; Honeycutt PJ; Soori G
    Cancer; 1998 May; 82(9):1677-81. PubMed ID: 9576288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
    Richards JM; Mehta N; Ramming K; Skosey P
    J Clin Oncol; 1992 Aug; 10(8):1338-43. PubMed ID: 1634924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
    Becker JC; Winkler B; Klingert S; Bröcker EB
    Cancer; 1994 Mar; 73(6):1621-4. PubMed ID: 8156489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 165.